ALNY - Alnylam Pharmaceuticals - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

ALNY is currently covered by 26 analysts with an average price target of $478.92. This is a potential upside of $43.82 (10.07%) from yesterday's end of day stock price of $435.1.

Alnylam Pharmaceuticals's activity chart (see below) currently has 418 price targets and 462 ratings on display. The stock rating distribution of ALNY is 75.51% BUY and 24.49% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 92.21% with an average time for these price targets to be met of 240.27 days.

Highest price target for ALNY is $500, Lowest price target is $268, average price target is $336.71.

Most recent stock forecast was given by JOSEPH STRINGER from NEEDHAM on 31-Jul-2025.

Currently out of the existing stock ratings of ALNY, 111 are a BUY (75.51%), 36 are a HOLD (24.49%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$478

$85.76 (21.86%)

$377

7 days ago
(31-Jul-2025)

21/22 (95.45%)

$85.76 (21.86%)

192

Buy

$370

$-22.24 (-5.67%)

$298

8 days ago
(30-Jul-2025)

10/10 (100%)

$30.2 (8.89%)

89

Buy

$348

$-44.24 (-11.28%)

$338

22 days ago
(16-Jul-2025)

7/7 (100%)

$25.19 (7.80%)

28

Buy

$359

$-33.24 (-8.47%)

$325

27 days ago
(11-Jul-2025)

9/9 (100%)

$44.06 (13.99%)

146

Buy

$384

$-8.24 (-2.10%)

$238

1 months ago
(07-Jul-2025)

8/8 (100%)

$59.87 (18.47%)

108

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is ALNY (Alnylam Pharmaceuticals) average time for price targets to be met?

On average it took 240.27 days on average for the stock forecasts to be realized with a an average price target met ratio 92.21

Which analyst has the current highest performing score on ALNY (Alnylam Pharmaceuticals) with a proven track record?

PATRICK TRUCCHIO

Which analyst has the most public recommendations on ALNY (Alnylam Pharmaceuticals)?

Patrick Trucchio has 11 price targets and 11 ratings on ALNY

Which analyst is the currently most bullish on ALNY (Alnylam Pharmaceuticals)?

Patrick Trucchio with highest potential upside - $107.76

Which analyst is the currently most reserved on ALNY (Alnylam Pharmaceuticals)?

Christopher Marai with lowest potential downside - -$318.24

Alnylam Pharmaceuticals in the News

ALNY Q2 Earnings Top Estimates on Higher Amvuttra Revenues, Stock Up

Alnylam Pharmaceuticals, Inc. ALNY reported second-quarter 2025 earnings of 32 cents per share, in contrast to the Zacks Consensus Estimate of a loss of 3 cents. The improvement was due to higher revenues from the sale of its lead drug, Amvuttra (vutrisiran). The company reported adjusted earnings of 56 cents in the year-ago quarter. Alnylam...

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Has Found A Path To Profitability

With the business potentially at an important milestone, we thought we’d take a closer look at Alnylam Pharmaceuticals, Inc.’s (NASDAQ:ALNY) future prospects. Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. With the latest financial year loss of US$278m and a trailing-twelve-month loss of US$270m, the US$44b market-cap company alleviated its...
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?